Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q4 2019 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$7.38M$7.38Mderived+12.2% vs Q4 2018 Net Income-$1.98M-$1.98MderivedN/M vs Q4 2018 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$4,472,849— Operating Incomederived-$2,318,462— Operating Cash Flowderived-$1,499,937N/M Free Cash Flowderived-$1,526,197N/M Margins · derivedGross margin60.6%
Operating margin-31.4%
Net margin-26.9%−25.2 pt vs Q4 2018
ended Dec 31, 2019 · filed Mar 26, 2020 · 86 d after period end